Down-regulation of Barx2 predicts poor survival in colorectal cancer
2016 (English)In: Biochemical and Biophysical Research Communications - BBRC, ISSN 0006-291X, E-ISSN 1090-2104, Vol. 478, no 1, 67-73 p.Article in journal (Refereed) Published
Human BarH-like homeobox 2 (Barx2), a homeodomain factor of the Bar family, has an important role in controlling the expression of cell adhesion molecules and has been reported in an increasing array of tumor types except colorectal cancer (CRC). The purpose of the current study was to characterize the expression of Barx2 and assess the clinical significance of Barx2 in CRC. First, we analyzed the expression of Barx2 in two independent public datasets from Oncomine. Subsequently, we evaluated Barx2 mRNA and protein expression by quantitative real-time PCR and western blotting, respectively. It was determined that Barx2 expression was lower in tumor tissues than in adjacent non-tumorous colorectal tissues of CRC patients, consistent with results from the public datasets. Subsequently, a tissue microarray containing 196 CRC specimens was evaluated for Barx2 expression by immunohistochemical staining. It was found that low expression of Barx2 significantly correlated with TNM stage, AJCC stage, differentiation, and relapse in patients with CRC. Patients with lower levels of Barx2 expression showed reduced disease-free survival and overall survival. Furthermore, a trend toward shorter overall survival in the patient group with Barx2-negative tumors independent of advanced AJCC stage and poor differentiation was determined by Kaplan-Meier survival analysis. Based on univariate and multivariate analyses, Barx2 expression was an independent prognostic factor for determining CRC prognosis. Taken together, low Barx2 expression was associated with the progression of CRC and could serve as a potential independent prognostic biomarker for patients with CRC. (C) 2016 The Authors. Published by Elsevier Inc.
Place, publisher, year, edition, pages
ACADEMIC PRESS INC ELSEVIER SCIENCE , 2016. Vol. 478, no 1, 67-73 p.
Colorectal cancer; Barx2; Progression; Prognosis
Cancer and Oncology
IdentifiersURN: urn:nbn:se:liu:diva-131884DOI: 10.1016/j.bbrc.2016.07.091ISI: 000381332800011PubMedID: 27453340OAI: oai:DiVA.org:liu-131884DiVA: diva2:1034920
Funding Agencies|National Natural Science Foundation of China 2016-10-132016-10-112016-10-13